JP2022137183A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2022137183A5 JP2022137183A5 JP2022111605A JP2022111605A JP2022137183A5 JP 2022137183 A5 JP2022137183 A5 JP 2022137183A5 JP 2022111605 A JP2022111605 A JP 2022111605A JP 2022111605 A JP2022111605 A JP 2022111605A JP 2022137183 A5 JP2022137183 A5 JP 2022137183A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- formulating
- seq
- amino acid
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims 15
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 102000004472 Myostatin Human genes 0.000 claims 2
- 108010056852 Myostatin Proteins 0.000 claims 2
- 108091005804 Peptidases Proteins 0.000 claims 2
- 239000004365 Protease Substances 0.000 claims 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 2
- 230000015572 biosynthetic process Effects 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 102000040430 polynucleotide Human genes 0.000 claims 2
- 108091033319 polynucleotide Proteins 0.000 claims 2
- 239000002157 polynucleotide Substances 0.000 claims 2
- 230000017854 proteolysis Effects 0.000 claims 2
- 239000003381 stabilizer Substances 0.000 claims 2
- 239000007853 buffer solution Substances 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024000878A JP7785107B2 (ja) | 2015-09-15 | 2024-01-05 | 抗プロ／潜在型ミオスタチン抗体およびその使用 |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562219094P | 2015-09-15 | 2015-09-15 | |
| US62/219,094 | 2015-09-15 | ||
| PCT/US2016/052014 WO2017049011A1 (en) | 2015-09-15 | 2016-09-15 | Anti-pro/latent-myostatin antibodies and uses thereof |
| JP2018513591A JP7107836B2 (ja) | 2015-09-15 | 2016-09-15 | 抗プロ／潜在型ミオスタチン抗体およびその使用 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018513591A Division JP7107836B2 (ja) | 2015-09-15 | 2016-09-15 | 抗プロ／潜在型ミオスタチン抗体およびその使用 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024000878A Division JP7785107B2 (ja) | 2015-09-15 | 2024-01-05 | 抗プロ／潜在型ミオスタチン抗体およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022137183A JP2022137183A (ja) | 2022-09-21 |
| JP2022137183A5 true JP2022137183A5 (enExample) | 2023-07-05 |
| JP7418508B2 JP7418508B2 (ja) | 2024-01-19 |
Family
ID=57043000
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018513591A Active JP7107836B2 (ja) | 2015-09-15 | 2016-09-15 | 抗プロ／潜在型ミオスタチン抗体およびその使用 |
| JP2022111605A Active JP7418508B2 (ja) | 2015-09-15 | 2022-07-12 | 抗プロ／潜在型ミオスタチン抗体およびその使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018513591A Active JP7107836B2 (ja) | 2015-09-15 | 2016-09-15 | 抗プロ／潜在型ミオスタチン抗体およびその使用 |
Country Status (25)
| Country | Link |
|---|---|
| US (3) | US10751413B2 (enExample) |
| EP (3) | EP3922645B1 (enExample) |
| JP (2) | JP7107836B2 (enExample) |
| KR (3) | KR20250033313A (enExample) |
| CN (4) | CN113896789A (enExample) |
| AU (2) | AU2016323447B2 (enExample) |
| BR (1) | BR112018004981A2 (enExample) |
| CA (1) | CA3036652A1 (enExample) |
| CO (1) | CO2018002703A2 (enExample) |
| CY (1) | CY1124619T1 (enExample) |
| DK (2) | DK3922645T3 (enExample) |
| EA (1) | EA038146B1 (enExample) |
| ES (2) | ES2881642T3 (enExample) |
| FI (1) | FI3922645T3 (enExample) |
| HR (2) | HRP20211081T1 (enExample) |
| HU (2) | HUE055331T2 (enExample) |
| IL (2) | IL305148A (enExample) |
| LT (2) | LT3922645T (enExample) |
| MX (5) | MX2018003196A (enExample) |
| PL (2) | PL3350220T3 (enExample) |
| PT (2) | PT3350220T (enExample) |
| RS (2) | RS62330B1 (enExample) |
| SI (2) | SI3922645T1 (enExample) |
| SM (2) | SMT202100432T1 (enExample) |
| WO (1) | WO2017049011A1 (enExample) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2006381T3 (en) | 2006-03-31 | 2016-02-22 | Chugai Pharmaceutical Co Ltd | PROCEDURE FOR REGULATING ANTIBODIES BLOOD PHARMACOKINETICS |
| DK2202245T3 (en) | 2007-09-26 | 2016-11-21 | Chugai Pharmaceutical Co Ltd | A method of modifying an antibody isoelectric point VIA amino acid substitution in CDR |
| PT2708559T (pt) | 2008-04-11 | 2018-05-16 | Chugai Pharmaceutical Co Ltd | Molécula de ligação ao antigénio capaz de se ligar repetidamente a duas ou mais moléculas de antigénio |
| MX365235B (es) | 2010-11-30 | 2019-05-28 | Chugai Pharmaceutical Co Ltd | Molécula de unión a antígeno capaz de unir repetidamente a la pluralidad de moléculas de antígeno. |
| WO2014030750A1 (ja) | 2012-08-24 | 2014-02-27 | 中外製薬株式会社 | マウスFcγRII特異的Fc抗体 |
| TWI855488B (zh) | 2012-08-24 | 2024-09-11 | 日商中外製藥股份有限公司 | FcγRIIb特異性Fc區域變異體 |
| SG11201508170TA (en) | 2013-04-02 | 2015-11-27 | Chugai Pharmaceutical Co Ltd | Fc REGION VARIANT |
| JP6706617B2 (ja) | 2014-11-06 | 2020-06-10 | スカラー ロック インコーポレイテッドＳｃｈｏｌａｒ Ｒｏｃｋ，Ｉｎｃ． | 抗プロ／潜在型−ミオスタチン抗体およびその使用 |
| MX2017005774A (es) | 2014-12-19 | 2017-07-28 | Chugai Pharmaceutical Co Ltd | Anticuerpos antimiostatina, polipeptidos que contienen regiones fc variantes, y metodos de uso. |
| SG11201706014PA (en) | 2015-02-05 | 2017-08-30 | Chugai Pharmaceutical Co Ltd | Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses therof |
| RS62330B1 (sr) | 2015-09-15 | 2021-10-29 | Scholar Rock Inc | Antitela pro/latentnog miostatina i njihova upotreba |
| JP7141336B2 (ja) | 2015-12-25 | 2022-09-22 | 中外製薬株式会社 | 抗ミオスタチン抗体および使用方法 |
| US10287345B2 (en) | 2016-01-08 | 2019-05-14 | Scholar Rock, Inc. | Methods for inhibiting myostatin activation by administering anti-pro/latent myostatin antibodies |
| KR20210082548A (ko) | 2016-06-13 | 2021-07-05 | 스칼러 락, 인크. | 미오스타틴 억제제의 용도 및 조합 요법 |
| KR102538749B1 (ko) | 2016-08-05 | 2023-06-01 | 추가이 세이야쿠 가부시키가이샤 | Il-8 관련 질환의 치료용 또는 예방용 조성물 |
| PT3565592T (pt) * | 2017-01-06 | 2023-05-31 | Scholar Rock Inc | Tratamento de doenças metabólicas através da inibição da ativação da miostatina |
| SI3565592T1 (sl) * | 2017-01-06 | 2023-05-31 | Scholar Rock, Inc. | Zdravljenje presnovnih bolezni z zaviranjem aktivacije miostatina |
| PT3677278T (pt) | 2018-07-11 | 2022-02-03 | Scholar Rock Inc | Inibidores seletivos da isoforma tgfbeta1 e sua utilização |
| JP7540994B2 (ja) | 2018-07-11 | 2024-08-27 | スカラー ロック インコーポレイテッド | 高親和性のアイソフォーム選択的ＴＧＦβ１阻害剤、およびその使用 |
| EA202192130A1 (ru) * | 2019-01-30 | 2021-12-28 | Сколар Рок, Инк. | Специфичные к ltbp-комплексу ингибиторы tgf и их применение |
| CN110429214B (zh) | 2019-08-07 | 2021-12-07 | 宁德时代新能源科技股份有限公司 | 二次电池的盖组件及二次电池 |
| SG11202009970VA (en) * | 2019-08-28 | 2021-04-29 | Chugai Pharmaceutical Co Ltd | Cross-Species Anti-Latent TGF-Beta 1 Antibodies And Methods Of Use |
| JP2023511255A (ja) | 2020-01-11 | 2023-03-17 | スカラー ロック インコーポレイテッド | ＴＧＦ－β阻害剤及びその使用 |
| RU2750267C1 (ru) * | 2020-02-07 | 2021-06-25 | Общество с ограниченной ответственностью «НАУЧНО-ПРОИЗВОДСТВЕННОЕ ОБЪЕДИНЕНИЕ ИН-ВЕТ» | Рекомбинантный ростовой дифференцировочный фактор роста 11 (GDF11), способ его получения, инъекционный препарат для повышения мышечной массы млекопитающих животных и птицы, а также способ использования препарата |
| EP4232151B1 (en) | 2020-10-26 | 2025-10-22 | Scholar Rock, Inc. | Use of anti-pro/latent myostatin antibody for treating spinal muscular atrophy |
| WO2022204581A2 (en) | 2021-03-26 | 2022-09-29 | Scholar Rock, Inc. | Tgf-beta inhibitors and use thereof |
| WO2022256723A2 (en) | 2021-06-03 | 2022-12-08 | Scholar Rock, Inc. | Tgf-beta inhibitors and therapeutic use thereof |
| WO2022271867A1 (en) | 2021-06-23 | 2022-12-29 | Scholar Rock, Inc. | A myostatin pathway inhibitor in combination with a glp-1 pathway activator for use in treating metabolic disorders |
| KR102840816B1 (ko) * | 2021-11-25 | 2025-07-31 | (주)네오크레마 | 근아세포의 증식과 근육세포로의 분화를 촉진하는 신규 펩티드 및 이의 용도 |
| KR102836354B1 (ko) * | 2021-11-25 | 2025-07-22 | (주)네오크레마 | 근아세포의 증식과 근육세포로의 분화를 촉진하는 신규 펩티드 및 이의 용도 |
| CA3251441A1 (en) | 2022-05-04 | 2023-11-09 | Scholar Rock Inc | USE OF A MYOSTATIN INHIBITOR FOR THE TREATMENT OF SPINAL MUSCULAR ATROPHY |
| IL319859A (en) | 2022-10-14 | 2025-05-01 | Genentech Inc | Methods for treating spinal muscular atrophy |
| KR20250122524A (ko) | 2022-12-22 | 2025-08-13 | 스칼러 락, 인크. | 미오스타틴 활성화의 선택적이고 강력한 억제 항체 |
| WO2024187051A1 (en) | 2023-03-07 | 2024-09-12 | Scholar Rock, Inc. | Tgf-beta inhibitors for use for treating resistant or unresponsive cancer in patients |
| WO2025240343A1 (en) | 2024-05-13 | 2025-11-20 | Scholar Rock, Inc. | Tgf-beta inhibitors for treating cancer |
Family Cites Families (114)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
| EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| US4777127A (en) | 1985-09-30 | 1988-10-11 | Labsystems Oy | Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus |
| GB8702816D0 (en) | 1987-02-07 | 1987-03-11 | Al Sumidaie A M K | Obtaining retrovirus-containing fraction |
| US5219740A (en) | 1987-02-13 | 1993-06-15 | Fred Hutchinson Cancer Research Center | Retroviral gene transfer into diploid fibroblasts for gene therapy |
| US5422120A (en) | 1988-05-30 | 1995-06-06 | Depotech Corporation | Heterovesicular liposomes |
| AP129A (en) | 1988-06-03 | 1991-04-17 | Smithkline Biologicals S A | Expression of retrovirus gag protein eukaryotic cells |
| EP1997891A1 (en) | 1988-09-02 | 2008-12-03 | Dyax Corporation | Generation and selection of recombinant varied binding proteins |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| EP0454781B1 (en) | 1989-01-23 | 1998-12-16 | Chiron Corporation | Recombinant cells for therapies of infection and hyperproliferative disorders and preparation thereof |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| DE69034168T3 (de) | 1989-03-21 | 2013-04-11 | Vical, Inc. | Expression von exogenen Polynukleotidsequenzen in Wirbeltieren |
| EP1645635A3 (en) | 1989-08-18 | 2010-07-07 | Oxford Biomedica (UK) Limited | Replication defective recombinant retroviruses expressing a palliative |
| US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| NZ237464A (en) | 1990-03-21 | 1995-02-24 | Depotech Corp | Liposomes with at least two separate chambers encapsulating two separate biologically active substances |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| AU665190B2 (en) | 1990-07-10 | 1995-12-21 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| WO1992009690A2 (en) | 1990-12-03 | 1992-06-11 | Genentech, Inc. | Enrichment method for variant proteins with altered binding properties |
| ATE439435T1 (de) | 1991-03-01 | 2009-08-15 | Dyax Corp | Chimäres protein mit mikroprotein mit zwei oder mehr disulfidbindungen und ausgestaltungen davon |
| DE69233750D1 (de) | 1991-04-10 | 2009-01-02 | Scripps Research Inst | Bibliotheken heterodimerer Rezeptoren mittels Phagemiden |
| DE4122599C2 (de) | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid zum Screenen von Antikörpern |
| DE69233013T2 (de) | 1991-08-20 | 2004-03-04 | The Government Of The United States Of America As Represented By The Secretary Of National Institute Of Health, Office Of Technology Transfer | Adenovirus vermittelter gentransfer in den gastrointestinaltrakt |
| WO1993010218A1 (en) | 1991-11-14 | 1993-05-27 | The United States Government As Represented By The Secretary Of The Department Of Health And Human Services | Vectors including foreign genes and negative selective markers |
| GB9125623D0 (en) | 1991-12-02 | 1992-01-29 | Dynal As | Cell modification |
| FR2688514A1 (fr) | 1992-03-16 | 1993-09-17 | Centre Nat Rech Scient | Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant. |
| JPH07507689A (ja) | 1992-06-08 | 1995-08-31 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 特定組織のターゲティング方法及び組成物 |
| JPH09507741A (ja) | 1992-06-10 | 1997-08-12 | アメリカ合衆国 | ヒト血清による不活性化に耐性のあるベクター粒子 |
| GB2269175A (en) | 1992-07-31 | 1994-02-02 | Imperial College | Retroviral vectors |
| CA2592997A1 (en) | 1992-12-03 | 1994-06-09 | Genzyme Corporation | Pseudo-adenovirus vectors |
| US5981568A (en) | 1993-01-28 | 1999-11-09 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
| US7393682B1 (en) * | 1993-03-19 | 2008-07-01 | The Johns Hopkins University School Of Medicine | Polynucleotides encoding promyostatin polypeptides |
| US5994618A (en) | 1997-02-05 | 1999-11-30 | Johns Hopkins University School Of Medicine | Growth differentiation factor-8 transgenic mice |
| CA2157577C (en) | 1993-03-19 | 2009-11-17 | Se-Jin Lee | Growth differentiation factor-8 |
| US7566768B1 (en) | 1995-10-26 | 2009-07-28 | The Johns Hopkins University School Of Medicine | Promyostatin peptides and methods of using same |
| AU6818094A (en) | 1993-04-22 | 1994-11-08 | Depotech Corporation | Cyclodextrin liposomes encapsulating pharmacologic compounds and methods for their use |
| JP3532566B2 (ja) | 1993-06-24 | 2004-05-31 | エル． グラハム，フランク | 遺伝子治療のためのアデノウイルスベクター |
| US6015686A (en) | 1993-09-15 | 2000-01-18 | Chiron Viagene, Inc. | Eukaryotic layered vector initiation systems |
| EP0694070B1 (en) | 1993-09-15 | 2002-04-10 | Chiron Corporation | Recombinant alphavirus vectors |
| JP3875990B2 (ja) | 1993-10-25 | 2007-01-31 | カンジ，インコーポレイテッド | 組換えアデノウイルスベクターおよび使用方法 |
| NZ276305A (en) | 1993-11-16 | 1997-10-24 | Depotech Corp | Controlled release vesicle compositions |
| WO1995030763A2 (en) | 1994-05-09 | 1995-11-16 | Chiron Viagene, Inc. | Retroviral vectors having a reduced recombination rate |
| CA2194660C (en) | 1994-07-08 | 2009-09-29 | Se-Jin Lee | Growth differentiation factor-11 |
| US20030167492A1 (en) | 1994-07-08 | 2003-09-04 | Johns Hopkins University School Of Medicine | Transgenic non-human animals expressing a gdf-11 dominant negative polypeptide, and methods of making and using same |
| WO1996017072A2 (en) | 1994-11-30 | 1996-06-06 | Chiron Viagene, Inc. | Recombinant alphavirus vectors |
| AU2998597A (en) | 1996-05-06 | 1997-11-26 | Chiron Corporation | Crossless retroviral vectors |
| US6891082B2 (en) | 1997-08-01 | 2005-05-10 | The Johns Hopkins University School Of Medicine | Transgenic non-human animals expressing a truncated activintype II receptor |
| US6656475B1 (en) | 1997-08-01 | 2003-12-02 | The Johns Hopkins University School Of Medicine | Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same |
| AU3734900A (en) | 1999-03-09 | 2000-09-28 | University Of Southern California | Method of promoting myocyte proliferation and myocardial tissue repair |
| AU2831801A (en) | 2000-01-28 | 2001-08-07 | Novo Nordisk A/S | Alkynylsubstituted propionic acid derivatives and their use against diabetes and obesity |
| EP2275449B1 (en) | 2000-06-16 | 2016-09-28 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to BLyS |
| AU2011244851A1 (en) | 2000-07-27 | 2011-11-24 | The John Hopkins University School Of Medicine | Promyostatin peptides and methods of using same |
| US7320789B2 (en) | 2001-09-26 | 2008-01-22 | Wyeth | Antibody inhibitors of GDF-8 and uses thereof |
| US8455627B2 (en) | 2001-10-05 | 2013-06-04 | Affimed Therapeutics, Ag | Human antibody specific for activated state of platelet integrin receptor GPIIb/IIIa |
| EP1300419B1 (en) | 2001-10-05 | 2007-06-13 | Affimed Therapeutics AG | Antibody of human origin for inhibiting thrombocyte aggregation |
| CN101745112A (zh) | 2002-07-19 | 2010-06-23 | 艾博特生物技术有限公司 | TNFα相关疾病的治疗 |
| BR0314270A (pt) | 2002-09-16 | 2005-08-02 | Univ Johns Hopkins | Ativação de miostatina com metaloprotease e processos de modulação da atividade da miostatina |
| US7261893B2 (en) * | 2002-10-22 | 2007-08-28 | Wyeth | Neutralizing antibodies against GDF-8 and uses therefor |
| JP4754219B2 (ja) * | 2002-12-02 | 2011-08-24 | アムジエン・フレモント・インコーポレイテツド | 腫瘍壊死因子を対象とする抗体、およびそれらの使用 |
| WO2005066204A2 (en) * | 2003-12-31 | 2005-07-21 | Schering-Plough Ltd. | Neutralizing epitope-based growth enhancing vaccine |
| EP1729793B1 (en) | 2004-03-02 | 2015-07-22 | Acceleron Pharma Inc. | Alk7 and myostatin inhibitors for muscle wasting disorders |
| EP1740946B1 (en) | 2004-04-20 | 2013-11-06 | Genmab A/S | Human monoclonal antibodies against cd20 |
| WO2005115439A2 (en) | 2004-05-27 | 2005-12-08 | Acceleron Pharma Inc. | Cerberus/coco derivatives and uses thereof |
| WO2006017538A2 (en) | 2004-08-03 | 2006-02-16 | Dyax Corp. | Hk1-binding proteins |
| EP1851245B1 (en) | 2005-01-26 | 2012-10-10 | Amgen Fremont Inc. | Antibodies against interleukin-1 beta |
| US20060216279A1 (en) | 2005-03-22 | 2006-09-28 | Glass David J | Myostatin inhibiting fusion polypeptides and therapeutic methods thereof |
| EA201100642A1 (ru) * | 2005-04-25 | 2011-12-30 | Пфайзер Инк. | Антитела к миостатину |
| PT2407486T (pt) | 2005-08-19 | 2018-02-21 | Univ Pennsylvania | Anticorpos antagonistas contra gdf-8 e utilizações no tratamento de ela e outros distúrbios associados a gdf-8 |
| CN101277976B (zh) | 2005-10-06 | 2012-04-11 | 伊莱利利公司 | 抗肌抑制素抗体 |
| UA92504C2 (en) * | 2005-10-12 | 2010-11-10 | Эли Лилли Энд Компани | Anti-myostatin monoclonal antibody |
| US8067562B2 (en) * | 2005-11-01 | 2011-11-29 | Amgen Inc. | Isolated nucleic acid molecule comprising the amino acid sequence of SEQ ID NO:1 |
| WO2007061995A2 (en) | 2005-11-21 | 2007-05-31 | Novartis Ag | Biomarkers for statin-induced myopathy or rhabdomyolysis |
| US8097596B2 (en) | 2006-06-30 | 2012-01-17 | Lakewood-Amedex, Inc. | Compositions and methods for the treatment of muscle wasting |
| ES2569365T3 (es) | 2006-11-29 | 2016-05-10 | Nationwide Children's Hospital | Inhibición de miostatina para la potenciación de músculo y/o la mejora de la función muscular |
| ATE542876T1 (de) | 2007-03-30 | 2012-02-15 | Merck Patent Gmbh | Doppelbrechungsschicht mit negativer optischer dispersion |
| EP2162152A2 (en) | 2007-06-01 | 2010-03-17 | Biogen Idec MA, Inc. | Cripto binding molecules |
| TW200918553A (en) | 2007-09-18 | 2009-05-01 | Amgen Inc | Human GM-CSF antigen binding proteins |
| PE20091163A1 (es) | 2007-11-01 | 2009-08-09 | Wyeth Corp | Anticuerpos para gdf8 |
| TW201029662A (en) | 2008-12-19 | 2010-08-16 | Glaxo Group Ltd | Novel antigen binding proteins |
| US8952130B2 (en) | 2009-02-24 | 2015-02-10 | The Salk Institute For Biological Studies | Designer ligands of TGF-β superfamily |
| NO2424895T3 (enExample) | 2009-04-27 | 2018-02-03 | ||
| CN102482339B (zh) | 2009-06-08 | 2015-06-17 | 阿塞勒隆制药公司 | 用于增加产热脂肪细胞的方法 |
| RS66008B1 (sr) | 2010-03-10 | 2024-10-31 | Genmab As | Monoklonska antitela protiv c-met |
| TWI667346B (zh) * | 2010-03-30 | 2019-08-01 | 中外製藥股份有限公司 | 促進抗原消失之具有經修飾的FcRn親和力之抗體 |
| JO3340B1 (ar) | 2010-05-26 | 2019-03-13 | Regeneron Pharma | مضادات حيوية لـعامل تمايز النمو 8 البشري |
| AR081556A1 (es) * | 2010-06-03 | 2012-10-03 | Glaxo Group Ltd | Proteinas de union al antigeno humanizadas |
| CA2808382A1 (en) * | 2010-08-16 | 2012-02-23 | Amgen Inc. | Antibodies that bind myostatin, compositions and methods |
| US8551892B2 (en) | 2011-07-27 | 2013-10-08 | Asm Japan K.K. | Method for reducing dielectric constant of film using direct plasma of hydrogen |
| US9700619B2 (en) | 2011-11-11 | 2017-07-11 | Duke University | Combination drug therapy for the treatment of solid tumors |
| US20130178454A1 (en) | 2011-11-17 | 2013-07-11 | Shalender Bhasin | Combination of testosterone and ornithine decarboxylase (odc) inhibitors |
| WO2013148284A1 (en) | 2012-03-29 | 2013-10-03 | Genentech, Inc. | Antibodies that bind to a pcsk9 cleavage site and methods of use |
| WO2013165972A2 (en) | 2012-04-30 | 2013-11-07 | Cell Signaling Technology, Inc. | Anti-hepatitis b virus antibodies and use thereof |
| WO2013186719A1 (en) | 2012-06-15 | 2013-12-19 | Pfizer Inc. | Improved antagonist antibodies against gdf-8 and uses therefor |
| MX388059B (es) | 2012-11-06 | 2025-03-19 | Scholar Rock Inc | Composiciones y metodos para modular la comunicacion celular. |
| CA2911514A1 (en) * | 2013-05-06 | 2014-11-13 | Scholar Rock, Inc. | Compositions and methods for growth factor modulation |
| EP2853898B1 (en) | 2013-09-27 | 2017-01-04 | Medizinische Hochschule Hannover | Analysis of myostatin in serum |
| US10004814B2 (en) | 2013-11-11 | 2018-06-26 | Sirna Therapeutics, Inc. | Systemic delivery of myostatin short interfering nucleic acids (siNA) conjugated to a lipophilic moiety |
| WO2015195094A1 (en) | 2014-06-17 | 2015-12-23 | Ember Therapeutics, Inc. | Anti-activin and nati-myostatin antibodies and methods of using the same |
| JP6706617B2 (ja) * | 2014-11-06 | 2020-06-10 | スカラー ロック インコーポレイテッドＳｃｈｏｌａｒ Ｒｏｃｋ，Ｉｎｃ． | 抗プロ／潜在型−ミオスタチン抗体およびその使用 |
| WO2016073879A2 (en) | 2014-11-06 | 2016-05-12 | Scholar Rock, Inc. | Transforming growth factor-related antibodies and uses thereof |
| MX2017005774A (es) * | 2014-12-19 | 2017-07-28 | Chugai Pharmaceutical Co Ltd | Anticuerpos antimiostatina, polipeptidos que contienen regiones fc variantes, y metodos de uso. |
| KR20170135967A (ko) | 2015-04-15 | 2017-12-08 | 리제너론 파마슈티칼스 인코포레이티드 | Gdf8 억제제를 사용하여 강도 및 기능을 증가시키는 방법 |
| RS62330B1 (sr) * | 2015-09-15 | 2021-10-29 | Scholar Rock Inc | Antitela pro/latentnog miostatina i njihova upotreba |
| US10287345B2 (en) * | 2016-01-08 | 2019-05-14 | Scholar Rock, Inc. | Methods for inhibiting myostatin activation by administering anti-pro/latent myostatin antibodies |
| KR20210082548A (ko) | 2016-06-13 | 2021-07-05 | 스칼러 락, 인크. | 미오스타틴 억제제의 용도 및 조합 요법 |
| JOP20190152A1 (ar) | 2016-12-21 | 2019-06-20 | Novartis Ag | مضادات الميوستاتين، الآكتيفين أو مستقبلات الآكتيفين للاستخدام في علاج السمنة والحالات ذات الصلة |
| SI3565592T1 (sl) | 2017-01-06 | 2023-05-31 | Scholar Rock, Inc. | Zdravljenje presnovnih bolezni z zaviranjem aktivacije miostatina |
-
2016
- 2016-09-15 RS RS20210987A patent/RS62330B1/sr unknown
- 2016-09-15 ES ES16774748T patent/ES2881642T3/es active Active
- 2016-09-15 US US15/760,393 patent/US10751413B2/en active Active
- 2016-09-15 HR HRP20211081TT patent/HRP20211081T1/hr unknown
- 2016-09-15 EA EA201890712A patent/EA038146B1/ru unknown
- 2016-09-15 EP EP21170667.6A patent/EP3922645B1/en active Active
- 2016-09-15 PT PT167747484T patent/PT3350220T/pt unknown
- 2016-09-15 SM SM20210432T patent/SMT202100432T1/it unknown
- 2016-09-15 RS RS20250592A patent/RS66913B1/sr unknown
- 2016-09-15 HU HUE16774748A patent/HUE055331T2/hu unknown
- 2016-09-15 CA CA3036652A patent/CA3036652A1/en active Pending
- 2016-09-15 LT LTEP21170667.6T patent/LT3922645T/lt unknown
- 2016-09-15 CN CN202111206744.5A patent/CN113896789A/zh active Pending
- 2016-09-15 CN CN202111206864.5A patent/CN113896790A/zh active Pending
- 2016-09-15 BR BR112018004981-6A patent/BR112018004981A2/pt active Search and Examination
- 2016-09-15 WO PCT/US2016/052014 patent/WO2017049011A1/en not_active Ceased
- 2016-09-15 AU AU2016323447A patent/AU2016323447B2/en active Active
- 2016-09-15 FI FIEP21170667.6T patent/FI3922645T3/fi active
- 2016-09-15 ES ES21170667T patent/ES3030258T3/es active Active
- 2016-09-15 CN CN201680065184.7A patent/CN108350067B/zh active Active
- 2016-09-15 PL PL16774748T patent/PL3350220T3/pl unknown
- 2016-09-15 HR HRP20250666TT patent/HRP20250666T1/hr unknown
- 2016-09-15 SI SI201631904T patent/SI3922645T1/sl unknown
- 2016-09-15 SM SM20250263T patent/SMT202500263T1/it unknown
- 2016-09-15 DK DK21170667.6T patent/DK3922645T3/da active
- 2016-09-15 JP JP2018513591A patent/JP7107836B2/ja active Active
- 2016-09-15 KR KR1020257005821A patent/KR20250033313A/ko active Pending
- 2016-09-15 LT LTEP16774748.4T patent/LT3350220T/lt unknown
- 2016-09-15 DK DK16774748.4T patent/DK3350220T3/da active
- 2016-09-15 PT PT211706676T patent/PT3922645T/pt unknown
- 2016-09-15 MX MX2018003196A patent/MX2018003196A/es unknown
- 2016-09-15 SI SI201631287T patent/SI3350220T1/sl unknown
- 2016-09-15 IL IL305148A patent/IL305148A/en unknown
- 2016-09-15 IL IL258121A patent/IL258121B2/en unknown
- 2016-09-15 EP EP24201758.0A patent/EP4461312A3/en active Pending
- 2016-09-15 HU HUE21170667A patent/HUE072064T2/hu unknown
- 2016-09-15 KR KR1020237037152A patent/KR102773636B1/ko active Active
- 2016-09-15 CN CN202111206951.0A patent/CN113912718B/zh active Active
- 2016-09-15 KR KR1020187010090A patent/KR102596852B1/ko active Active
- 2016-09-15 PL PL21170667.6T patent/PL3922645T3/pl unknown
- 2016-09-15 EP EP16774748.4A patent/EP3350220B1/en active Active
-
2018
- 2018-03-14 MX MX2022005202A patent/MX2022005202A/es unknown
- 2018-03-14 CO CONC2018/0002703A patent/CO2018002703A2/es unknown
- 2018-03-14 MX MX2022005177A patent/MX2022005177A/es unknown
- 2018-03-14 MX MX2022005173A patent/MX2022005173A/es unknown
- 2018-03-14 MX MX2022005211A patent/MX2022005211A/es unknown
-
2020
- 2020-06-24 US US16/946,483 patent/US11439704B2/en active Active
-
2021
- 2021-08-10 CY CY20211100716T patent/CY1124619T1/el unknown
-
2022
- 2022-07-12 JP JP2022111605A patent/JP7418508B2/ja active Active
- 2022-07-21 US US17/814,221 patent/US20230190929A1/en active Pending
-
2023
- 2023-06-21 AU AU2023203922A patent/AU2023203922A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022137183A5 (enExample) | ||
| CN101426905B (zh) | 从细胞培养物分离纯化的水泡性口炎病毒的纯化方法 | |
| JP2022046771A (ja) | ペプチド模倣大環状分子およびその製剤 | |
| EP0841942B2 (fr) | Procede de production industrielle d'un vaccin contre l'encephalite japonaise et vaccin obtenu | |
| JP2013512889A5 (enExample) | ||
| RU2011127913A (ru) | Составы, содержащие антитела | |
| CN107022008A (zh) | 广谱地抑制人类冠状病毒感染的多肽及其应用 | |
| JP2014097057A5 (enExample) | ||
| JP2014531910A5 (enExample) | ||
| RU2011137030A (ru) | Способы очистки малых модулярных иммунофармацевтических белков | |
| JP2013511481A5 (enExample) | ||
| CN115925826B (zh) | 一种抗新型冠状病毒的多肽及其应用 | |
| JP2018524019A5 (enExample) | ||
| CN101481415A (zh) | 一种新型prrs病毒受体及该受体的阻断抑制剂 | |
| JP2019528242A5 (enExample) | ||
| CN1458280A (zh) | 两个人工合成prrs病毒多表位串联核苷酸序列及应用 | |
| RU2014138418A (ru) | Белки пилей и композиции | |
| JPWO2008038599A1 (ja) | 軸索再生促進剤 | |
| EP3515479A1 (en) | Treatment and/or prevention of sepsis | |
| JP2011079808A (ja) | Ｓｔｘ毒性阻害ペプチドおよびＳｔｘに起因する疾患の治療薬 | |
| WO2018038168A1 (ja) | ヘマグルチニン結合ペプチド、および、これを含むインフルエンザウイルス感染症の予防・治療薬 | |
| CN1839837A (zh) | 尼可地尔冻干粉的制备方法 | |
| CN117379544B (zh) | 一种抗体组合物及其在制备抗新冠病毒的药物中的应用 | |
| CN113368063A (zh) | 一种注射用重组白细胞抑制因子和水蛭肽嵌合蛋白冻干制剂及其制备方法 | |
| JPH04504407A (ja) | Ｐｄｇｆ―ａ，ｐｄｇｆ―ａａ，ｐｄｇｆ―ａｂ，その生産方法及びそれを含む医薬 |